肿瘤细胞治疗研究
英文原题：The promise of TIL therapy for glioblastoma.
TIL（肿瘤浸润淋巴细胞）疗法已在难治性黑色素瘤中显示出疗效，并在肺癌中产生持久缓解。
TIL（肿瘤浸润淋巴细胞）疗法已在难治性黑色素瘤中显示出疗效，并在肺癌中产生持久缓解。胶质母细胞瘤对免疫治疗提出了独特挑战，包括显著的肿瘤异质性、低T细胞浸润和免疫抑制性微环境，但这些相同特征也凸显了TILs的独特理论基础。与单克隆工程化方法不同，TILs保留天然多克隆性，使其能够识别多种肿瘤相关抗原，并有可能适应不断演变的抗原景观。初步研究已表明，肿瘤反应性TILs可从胶质母细胞瘤标本中成功分离并扩增，为临床转化提供了可行性。本综述讨论了TIL疗法在胶质母细胞瘤中的当前现状，重点介绍了近期进展，并探讨了未来方向和临床转化，以将TIL疗法定位为一种有前景且具有适应性的细胞免疫疗法，用于治疗最具治疗抵抗性的人类癌症之一。
Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy in refractory melanoma and durable responses in lung cancer. Glioblastoma presents distinct challenges for immunotherapy, including profound tumor heterogeneity, low T cell infiltration, and an immunosuppressive microenvironment, but these same features highlight the unique rationale for TILs. Unlike monoclonal engineered approaches, TILs retain natural polyclonality, enabling recognition of a diverse set of tumor-associated antigens and potential adaptation to the evolving antigenic landscape. Preliminary studies have already shown that tumor-reactive TILs can be successfully isolated and expanded from glioblastoma specimens, providing feasibility for clinical translation. This review discusses the current landscape of TIL therapy in glioblastoma, highlights recent advancements, and discusses future directions and clinical translation to position TIL therapy as a promising and adaptable cellular immunotherapy for one of the most treatment-resistant human cancers.
MEMBER ACCOUNT
登录成功会直接打开下一页。
